Table A1.
A-NB94 Staging Criteria | Retrospective INRG Risk Classification | ||||||
---|---|---|---|---|---|---|---|
MYCN | Stage | Age | Low | Intermediate | High | n.e. | Total |
amplified | 1 | ≤12 | 1 | 1 | |||
>12 | 1 | 1 | |||||
2 | ≤12 | ||||||
>12 | |||||||
3 | ≤12 | 1 | 1 | ||||
>12 | 4 | 4 | |||||
4 | ≤12 | 5 | 5 | ||||
>12 | 14 | 14 | |||||
non-amplified | 1 | ≤12 | 15 | 15 | |||
>12 | 46 | 46 | |||||
2 | ≤12 | 9 | 9 | ||||
>12 | 10 | 10 | |||||
3 | ≤12 | 8 | 4 | 12 | |||
>12 | 3 | 3 | 1 | 7 | |||
4 | ≤12 | 4 | 1 | 1 | 6 | ||
>12 | 17 | 1 | 18 | ||||
4S | ≤12 | 4 | 6 | 10 | |||
heterogeneously amplified | 1 | ≤12 | 1 | 1 | |||
>12 | |||||||
2 | ≤12 | 1 | 1 | ||||
>12 | |||||||
3 | ≤12 | 1 | 1 | ||||
>12 | |||||||
4 | ≤12 | 1 | 1 | ||||
>12 | |||||||
Total | 102 | 4 | 43 | 14 | 163 |
Retrospective correlation of A-NB94 risk stratification with the International Neuroblastoma Risk Group (INRG) classification [2].